• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (CSE:BIOV)

0.1800 -0.0350 (-16.28%)
Streaming Delayed Price Updated: 12:25 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377,265
Open 0.2050
Bid (Size) 0.1850 (17,000)
Ask (Size) 0.1900 (8,000)
Prev. Close 0.2150
Today's Range 0.1200 - 0.2100
52wk Range 0.0200 - 0.3100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
January 29, 2026
Via TheNewswire.com
News headline image
BioVaxys 1Q2026 R&D and Collaborative Activity
January 15, 2026
Via TheNewswire.com

Performance

YTD
-21.7%
-21.7%
1 Month
-21.7%
-21.7%
3 Month
-34.5%
-34.5%
6 Month
+700.0%
+700.0%
1 Year
+200.0%
+200.0%

More News

Read More
News headline image
2025 Corporate Review
December 31, 2025
Via TheNewswire.com
News headline image
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
December 17, 2025
Via Newsfile
News headline image
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
December 15, 2025
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioVaxys Technology Corp. Closes Debt Settlement Transaction
November 25, 2025
Via TheNewswire.com
News headline image
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
November 19, 2025
Via TheNewswire.com
Topics Intellectual Property
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
April 22, 2025
Via Investor Brand Network
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
September 17, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
April 18, 2023
Via ACCESSWIRE
News headline image
The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
March 16, 2023
Via ACCESSWIRE
News headline image
The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
December 20, 2022
Via ACCESSWIRE
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Via FinancialNewsMedia
News headline image
The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
October 06, 2022
Via ACCESSWIRE
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Via FinancialNewsMedia
News headline image
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Via FinancialNewsMedia
News headline image
The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
September 28, 2022
Via ACCESSWIRE
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Via FinancialNewsMedia
Topics Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Via FinancialNewsMedia
News headline image
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Via FinancialNewsMedia
Topics Economy
News headline image
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
March 30, 2022
From The Market Herald
Via AccessWire

Frequently Asked Questions

Is Biovaxys Technology Corp publicly traded?
Yes, Biovaxys Technology Corp is publicly traded.
What exchange does Biovaxys Technology Corp trade on?
Biovaxys Technology Corp trades on the Canadian Securities Exchange
What is the ticker symbol for Biovaxys Technology Corp?
The ticker symbol for Biovaxys Technology Corp is BIOV on the Canadian Securities Exchange
What is the current price of Biovaxys Technology Corp?
The current price of Biovaxys Technology Corp is 0.1800
When was Biovaxys Technology Corp last traded?
The last trade of Biovaxys Technology Corp was at 01/30/26 12:25 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap